301 related articles for article (PubMed ID: 22711060)
1. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; de Castria TB; Cruz MR; Riera R
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; Castria TB; Cruz MR; Riera R
Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
[TBL] [Abstract][Full Text] [Related]
5. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Yu Y; Xu X; Du Z; Shi M
Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Yang J; He J; Yu M; Li T; Luo L; Liu P
Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
[TBL] [Abstract][Full Text] [Related]
8. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
10. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
13. Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.
Xu CA; Chang ZY; Wang XJ; Qi HY
Int J Clin Pract; 2013 Nov; 67(11):1118-27. PubMed ID: 24165426
[TBL] [Abstract][Full Text] [Related]
14. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
Russo A; Rizzo S; Fulfaro F; Adamo V; Santini D; Vincenzi B; Gebbia N; Carreca I
Cancer; 2009 May; 115(9):1924-31. PubMed ID: 19235250
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Gao G; Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Lung Cancer; 2009 Sep; 65(3):339-44. PubMed ID: 19144444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
